Broad Modulation of Tissue Responses (Immune Activation) by Celacade May Favorably Influence Pathologic Processes Associated with Heart Failure Progression
- 1 June 2005
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 95 (11) , 30-37
- https://doi.org/10.1016/j.amjcard.2005.03.010
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Targeted Anticytokine Therapy in Patients With Chronic Heart FailureCirculation, 2004
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Immunohistological Changes in Dilated Cardiomyopathy Induced by Immunoadsorption Therapy and Subsequent Immunoglobulin SubstitutionCirculation, 2001
- Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart FailureCirculation, 2001
- Role of cytokines in heart failureAmerican Heart Journal, 1998
- Basic Mechanisms in Congestive Heart FailureChest, 1994
- Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs.Journal of Clinical Investigation, 1992
- Negative Inotropic Effects of Cytokines on the Heart Mediated by Nitric OxideScience, 1992
- A Prospective, Randomized, Controlled Trial of Prednisone for Dilated CardiomyopathyNew England Journal of Medicine, 1989
- Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response.Circulation, 1986